BRIEF-Rhythm Pharmaceuticals Announces Progress In Clinical Development Of Setmelanotide


Jan 4 (Reuters) – Rhythm Pharmaceuticals Inc:

* RHYTHM PHARMACEUTICALS ANNOUNCES PROGRESS IN CLINICAL DEVELOPMENT OF SETMELANOTIDE FOR TREATMENT OF RARE GENETIC DISORDERS OF OBESITY

* RHYTHM PHARMACEUTICALS – SETMELANOTIDE GRANTED ORPHAN DRUG DESIGNATION FOR TREATMENT OF LEPTIN RECEPTOR (LEPR) DEFICIENCY OBESITY

* RHYTHM PHARMACEUTICALS – FINALIZED PROTOCOL FOR PIVOTAL PHASE 3 CLINICAL TRIAL IN PRO-OPIOMELANOCORTIN (POMC) DEFICIENCY OBESITY

* RHYTHM PHARMACEUTICALS – CONFIRMS PLANS TO FILE NDA WITH FDA BASED ON ONE-YEAR DATA FROM 10 PATIENT COHORT IN POMC PHASE 3 CLINICAL TRIAL Source text for Eikon: Further company coverage:


Read First From Source http://feeds.reuters.com/~r/reuters/companyNews/~3/h6BY7-M6YHg/brief-rhythm-pharmaceuticals-announces-progress-in-clinical-development-of-setmelanotide-idUSFWN1OZ0N8

Learn More about Forex SignalForex Signal Service

What do you think?

0 points
Upvote Downvote

Total votes: 0

Upvotes: 0

Upvotes percentage: 0.000000%

Downvotes: 0

Downvotes percentage: 0.000000%

US STOCKS-Dow tops 25,000 on strong private hiring, global growth hopes

Citibank fined $70 million for anti-money laundering compliance shortcomings